Currently, there are 54.94M common shares owned by the public and among those 49.14M shares have been available to trade.
The company’s stock has a 5-day price change of 110.82% and 61.29% over the past three months. PASG shares are trading 11.88% year to date (YTD), with the 12-month market performance up to 71.19% higher. It has a 12-month low price of $0.45 and touched a high of $1.79 over the same period. PASG has an average intraday trading volume of 513.09K shares. The stock is trading above its simple moving averages at the SMA20, SMA50, and SMA200, as the current price level is off by 82.21%, 81.90%, and 14.31% respectively.
Institutional ownership of Passage Bio Inc (NASDAQ: PASG) shares accounts for 43.41% of the company’s 54.94M shares outstanding.
It has a market capitalization of $118.32M and a beta (3y monthly) value of 1.22. The earnings-per-share (ttm) stands at -$1.17. Price movements for the stock have been influenced by the stock’s volatility, which stands at 35.28% over the week and 16.68% over the month.
Earnings per share for the fiscal year are expected to increase by 42.26%, and 29.93% over the next financial year.
Looking at the support for the PASG, a number of firms have released research notes about the stock. Wedbush stated their Outperform rating for the stock in a research note on November 29, 2024, with the firm’s price target at $3-$4. Rodman & Renshaw coverage for the Passage Bio Inc (PASG) stock in a research note released on September 03, 2024 offered a Buy rating with a price target of $7. JP Morgan was of a view on March 08, 2022 that the stock is Neutral, while Goldman gave the stock Neutral rating on January 19, 2022, issuing a price target of $29- $6. Raymond James on their part issued Outperform rating on July 01, 2021.
